Plain-English translation of NCT07774975 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage study is testing a new medication called (pitavastatin encapsulated in nanoparticles) given through an IV infusion to treat retinitis pigmentosa (RP), a rare inherited eye disease that gradually damages light-sensitive cells in the retina and causes vision loss. The medication is designed to reduce harmful inflammation in the eye that may be contributing to vision loss. Researchers hope this treatment could slow disease progression, though this is the first time it's being tested in patients.
Currently, there are very few treatment options that can slow retinitis pigmentosa. Research suggests that inflammation in the eye—particularly from certain immune cells—may be driving the loss of vision-sensing cells. This trial is testing whether this new anti-inflammatory medication could address that underlying problem.
You likely qualify if…
You likely don't qualify if…
In the first part of the study, you will receive a single IV infusion of the medication at a low dose, and researchers will carefully monitor you for any side effects. If the medication appears safe, the second part involves receiving three more infusions spaced four weeks apart at a higher dose. Throughout the study, you'll have eye exams, blood tests, and measurements of vision and eye inflammation to evaluate how well the medication is tolerated and whether it helps preserve vision.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Japan